早期乳腺癌新辅助随机临床试验中总生存的替代终点
该分析纳入11项新辅助随机临床试验的个体患者数据(共15个治疗比较、12247例患者),评估病理完全缓解(pCR)和无侵袭性疾病生存(iDFS)对总生存(OS)的试验水平替代价值。pCR与OS治疗效应的关联弱(R²=0.07),iDFS与OS的关联总体R²=0.46,随访充足时iDFS是可接受的OS替代终点。
要点
- pCR对OS的替代价值弱,R²=0.07(95%CI 0.00-0.48)。
- iDFS对OS总体R²=0.46(95%CI 0.08-0.71),略低于中度替代阈值0.5。
- 随访至36个月时iDFS替代价值明显增加,48个月后改善有限。
核心结论
- 随访充足的iDFS是可接受的替代终点,可自信预测早期乳腺癌新辅助随机临床试验的最终OS结果。
- 该推荐适用于许多亚组,但激素受体阳性(HR+)疾病是显著例外。
- 明确需要重新评估OS是否为HR+早期乳腺癌疗效测定的最佳终点。
研究设计与样本
- 纳入具有pCR、iDFS和OS数据的早期乳腺癌新辅助随机临床试验的个体患者数据。
- 共纳入11项随机临床试验,15个治疗比较,12247例患者。
- 采用加权线性回归模型的决定系数R²量化OS治疗效应与替代终点治疗效应之间的关联。
主要发现
- OS风险比与pCR比值比的总体关联弱,R²=0.07(95%CI 0.00-0.48),在所有探索的亚组中亦然。
- OS风险比与iDFS风险比的总体R²=0.46(95%CI 0.08-0.71),略低于中度替代阈值0.5。
- 在大多数探索的亚组中R²范围为0.5至<0.7;在激素受体阴性/人表皮生长因子受体2阴性亚型、组织学分级1-2级肿瘤和小叶肿瘤中替代性强(即R²≥0.7)。
- iDFS对OS的替代价值受随访时间影响:随访至36个月时R²大幅增加,48个月后进一步改善很小。
关键数值与推荐
- pCR对OS的替代价值:总体R²=0.07(95%CI 0.00-0.48)。
- iDFS对OS的替代价值:总体R²=0.46(95%CI 0.08-0.71),中度替代阈值为0.5。
- 大多数亚组R²为0.5至<0.7;激素受体阴性/人表皮生长因子受体2阴性亚型、组织学分级1-2级肿瘤和小叶肿瘤中R²≥0.7。
- 随访至36个月时R²大幅增加,48个月后进一步改善很小。
临床怎么用
- 作者认为随访充足的iDFS是可接受的替代终点,可自信预测早期乳腺癌新辅助随机临床试验的最终OS结果。
- 作者指出该推荐适用于许多亚组,但HR+疾病是显著例外。
- 作者认为明确需要重新评估OS是否为HR+早期乳腺癌疗效测定的最佳终点。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To assess trial-level surrogacy value for overall survival (OS) of the pathologic complete response (pCR) and invasive disease-free survival (iDFS) in randomized clinical trials (RCTs) for early breast cancer (BC). METHODS: Individual patient data of neoadjuvant RCTs with available data on pCR, iDFS, and OS were included in the analysis. We used the coefficient of determination R2 from weighted linear regression models to quantify the association between treatment effects on OS and on the surrogate end points. RESULTS: Eleven RCTs, for a total of 15 treatment comparisons and 12,247 patients, were included in the analysis. There was a weak association between hazard ratios (HRs) for OS and odds ratio of pCR overall (R2, 0.07; 95% CI, 0.00 to 0.48), as well as in all the subgroups explored. Overall, the R2 for the association between HR OS and HR iDFS was 0.46 (95% CI, 0.08 to 0.71), which is just below the cutoff of 0.5 for moderate surrogacy. In the majority of subgroups explored, the R2 ranged from 0.5 to <0.7, while in hormone receptor-/human epidermal growth factor receptor 2- subtype, histologic grade 1-2 tumors, and lobular tumors, surrogacy was strong (ie, R2 ≥0.7). The surrogacy value of iDFS for OS was affected by follow-up (FUP) length: R2 substantially increased up to 36 months of FUP, with little further improvement after 48 months of FUP. CONCLUSION: iDFS with sufficient FUP is an acceptable surrogate end point to confidently anticipate final OS results of neoadjuvant RCTs for early BC. This recommendation holds true across many subgroups, with the notable exception of HR+ disease. There is definite need to reassess whether OS is the optimal end point for treatment efficacy measurement in HR+ early BC.
引用
- Conforti F, Nekljudova V, Sala I, et al. Surrogate End Points for Overall Survival in Neoadjuvant Randomized Clinical Trials for Early Breast Cancer. J Clin Oncol. 2025. PMID: 39883887. doi:10.1200/JCO-24-01360
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。